

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 January 2025 (02.01.2025)



(10) International Publication Number
WO 2025/003978 A1

(51) International Patent Classification:

A61M 5/32 (2006.01) *A61P 11/04* (2006.01)
A61B 17/34 (2006.01) *A61P 21/00* (2006.01)
A61K 31/7088 (2006.01) *C12N 7/00* (2006.01)
A61K 38/17 (2006.01) *C12N 15/113* (2010.01)
A61K 48/00 (2006.01) *C12N 15/86* (2006.01)

(72) Inventors: **MUKADAM, Sophie**; c/o Benitec Biopharma Inc., 3940 Trust Way, Hayward, California 94545 (US). **BANKS, Jerel**; c/o Benitec Biopharma Inc., 3940 Trust Way, Hayward, California 94545 (US). **ST-GUILY, Jean Lacau**; c/o Benitec Biopharma Inc., 3940 Trust Way, Hayward, California 94545 (US).

(21) International Application Number:

PCT/IB2024/056310

(22) International Filing Date:

28 June 2024 (28.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/510,750 28 June 2023 (28.06.2023) US

(71) Applicant: **BENITEC IP HOLDINGS INC.** [US/US]; Corporation Trust Centre, 1209 Orange Street, City of Wilmington, Delaware 19801 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV,

(54) Title: DEVICE AND METHODS FOR ADMINISTERING A THERAPEUTIC COMPOSITION TO THE PHARYNGEAL MUSCLE




Fig. 1

(57) Abstract: The present disclosure relates to devices and methods for administration of a therapeutic composition to the pharyngeal muscle. In particular, the devices and methods of the disclosure may be used in treatment or prevention of dysphagia, including dysphagia associated with oropharyngeal muscular dystrophy (OPMD) in individuals suffering therefrom or predisposed thereto. Additionally, the present disclosure relates to devices and methods used to deliver modified adeno-associated virus (AAV) delivery vectors comprising 'silence and replace' DNA constructs, including compositions comprising same.

[Continued on next page]

WO 2025/003978 A1

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*